Results 81 to 90 of about 16,507 (152)

Aldosterone Breakthrough for the Prediction of Treatment Response to Mineralocorticoid Receptor Antagonists. [PDF]

Kidney Med
Imcaoudene AR, Najjar C, Marques P, Tsoukas MA, Sharma A, Mavrakanas TA.   +5 more
europepmc   +1 more source

Renin-guided therapy with mineralocorticoid receptor antagonists in primary aldosteronism: feasibility study (RETAME-PA) - a clinical research protocol for a randomised controlled trial. [PDF]

BMJ Open
Merabtine A, Leung AA, Kline GA, Dubrofsky L, Hundemer GL, Goupil R.   +5 more
europepmc   +1 more source

The Effect of Mineralocorticoid Receptor Antagonists on Heart Failure with Nonreduced Ejection Fraction: A Systematic Review and Meta-Analysis. [PDF]

CJC Open
De Luca C, Bhatt H, Gupta A, Yahyavi A, Banivaheb B, Rayner D, Anderson K, Zieroth S, Virani SA, Foroutan F, Aleksova N.   +10 more
europepmc   +1 more source

Adrenal venous sampling outcomes with and without mineralocorticoid receptor antagonists in primary aldosteronism. [PDF]

BMC Endocr Disord
Thipbumrung S, Manosroi W.
europepmc   +1 more source

Investigating the efficacy of mineralocorticoid receptor antagonists for cardiovascular outcomes in different diseases. [PDF]

ESC Heart Fail
Wang J, Zheng M, Yang Y, Zhang L, Wulasihan M.   +4 more
europepmc   +1 more source

Will mineralocorticoid receptor antagonists give impact on HFpEF pharmacotherapy in addition to SGLT2 inhibitors? [PDF]

Eur Heart J Cardiovasc Pharmacother
Komiyama M, Hasegawa K, Rosano GMC.
europepmc   +1 more source

Dose optimization and utilization trends of mineralocorticoid receptor antagonists in heart failure patients with reduced ejection fraction in Ethiopia. [PDF]

Am Heart J Plus
Hassen M, Worku BT, Solomon T, Demessie MB, Wendie TF, Muhammed OS, Gobezie MY.   +6 more
europepmc   +1 more source

An individual treatment effect approach to predict response to mineralocorticoid receptor antagonists in patients with heart failure and reduced ejection fraction. [PDF]

Eur J Heart Fail
Kobayashi M, Duarte K, Ferreira JP, Baudry G, Monzo L, McMurray JJV, Van Veldhuisen DJ, Pitt B, Zannad F, Girerd N.   +9 more
europepmc   +1 more source

Aldosterone-Related Cardiovascular Disease and Benefits of Mineralocorticoid Receptor Antagonists in Clinical Practice. [PDF]

JACC Adv
Alfarano M, Marchionni G, Costantino J, Ballatore F, Verardo R, Miraldi F, Ciciarello FL, Petramala L, Letizia C, Frustaci A, Chimenti C.   +10 more
europepmc   +1 more source

Combination therapy with mineralocorticoid receptor antagonists and SGLT2 inhibitors versus SGLT2 inhibitor monotherapy in chronic kidney disease: an updated meta-analysis of randomized controlled trials. [PDF]

BMC Nephrol
Muhammad Daniyal S, Ajaz H, Riaz M, Murad Khatoon N, Aftab Z, Tauqir Gondal H, Gul I, Sarwar M, Batool F, Fahim SL, Noor A, Khalid A, Ashraf DA, Jabarkhil R.   +13 more
europepmc   +1 more source